Anonymous
Guest
Anonymous
Guest
In rereading the email about Dulera, it states that we should segregate in red letters, then wait to hear about the disposition of the samples. Why do we have to send all these sample back? When Avelox got a "packaging update" we did not send them back, the company just sent new PIs. Also, why would they include Asmanex HFA, when we are not authorized to start talking about it yet? I don't agree with the rumors of the contract ending,but something is not right.
Exactly (to the above poster)! Who cares if fluticasone is hitting the OTC shelves soon. Until the PBMs kick Nasonex off, keep it on the doctors shelves! Something is definitely is not right.